PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Both companies show declining cash positions (-7.59% vs TRVN's -5.66%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Cash + STI yoy 1.25-1.5x TRVN's -5.66%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x TRVN's -35.31%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-8.57%
0.75-0.9x TRVN's -10.82%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-5.56%
1.25-1.5x TRVN's -4.18%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to TRVN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Similar yoy growth to TRVN's -4.51%. Walter Schloss finds parallel expansions in non-current assets.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
0.75-0.9x TRVN's -10.03%. Bill Ackman questions if competitor invests more aggressively for growth.
-2.42%
Less than half of TRVN's 49.06%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
-3.64%
Higher Other Current Liabilities Growth compared to TRVN's zero value, indicating worse performance.
-2.05%
Less than half of TRVN's 22.71%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Less than half of TRVN's 14.90%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of TRVN's 16.06%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Less than half of TRVN's 13.33%. David Dodd sees fewer share issuances vs. competitor.
-2.84%
Similar yoy to TRVN's -2.89%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
Below half TRVN's -315.75%. Michael Burry sees potential underperformance in building shareholder capital.
-8.43%
0.75-0.9x TRVN's -10.03%. Bill Ackman wonders if competitor invests or leverages more aggressively.
0.97%
Higher Total Investments Growth compared to TRVN's zero value, indicating better performance.
-4.43%
Less than half of TRVN's 2.64%. David Dodd sees less overall debt expansion vs. competitor.
7.68%
Less than half of TRVN's 805.82%. David Dodd sees better deleveraging or stronger cash buildup than competitor.